XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity of Utah
About this trial
The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants will return to clinic for regular visits for checkups and tests.
Eligibility criteria
Qualifiers
Participant aged ≥ 18 years
Radiographic evidence of metatstatic disease
Progression on or after prior treatment with 177Lu-PSMA-617 as determined by clinical investigator
ECOG Performance Status ≤ 2.
Disqualifiers
Prior treatment with XL092
Receipt of any type of small molecule kinase inhibitor, cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 2 weeks or at least 5 half-lives, whichever shorter before first dose of study treatment.
Radiation therapy for bone metastasis or any other radiation therapy within 2 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
Trial design
Treatments tested in this trial
- XL092
Treatment groups
32 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Utah
Lead sponsor
Exelixis
Collaborator
Source ClinicalTrials.gov